BNTC (Benitec Biopharma) ROC (Joel Greenblatt) %: -5,612.40% (As of Mar. 2026)


BNTC Benitec Biopharma Inc BNTC
34 GF Score
Price $13.21
View Full Analysis

What is Benitec Biopharma ROC (Joel Greenblatt) %?

Benitec Biopharma BNTC +4.34% 34 ROC (Joel Greenblatt) % is -5,612.40% as of Mar. 2026. GuruFocus rates BNTC with a GF Score™ of 34/100. Among 1,324 Biotechnology companies, Benitec Biopharma ranks worse than 84.29% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Benitec Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -5,612.40%.

The historical rank and industry rank for Benitec Biopharma's ROC (Joel Greenblatt) % or its related term are showing as below:

BNTC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5800.69   Med: -2141.82   Max: 733.81
Current: -4745.98

During the past 12 years, Benitec Biopharma's highest ROC (Joel Greenblatt) % was 733.81%. The lowest was -5800.69%. And the median was -2141.82%.

BNTC's ROC (Joel Greenblatt) % is ranked worse than
84.29% of 1324 companies
in the Biotechnology industry
Industry Median: -297.06 vs BNTC: -4745.98

Benitec Biopharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -32.80% per year.


Benitec Biopharma  (NAS:BNTC) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Benitec Biopharma ROC (Joel Greenblatt) % Related Terms


Benitec Biopharma ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Benitec Biopharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Benitec Biopharma ROC (Joel Greenblatt) % Chart

Benitec Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,968.23 -2,315.41 -2,376.21 -4,235.40 -5,800.69

Benitec Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,781.68 -3,746.29 -4,207.30 -5,653.25 -5,612.40

BNTC vs IPSC, FBRX, AUTL: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Benitec Biopharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's ROC (Joel Greenblatt) % falls into.


BNTC
34GF Score
Benitec Biopharma Inc BNTC
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Benitec Biopharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.13 + 0 + 0.67500000000001) - (1.85 + 0 + 0.483)
=-1.528

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.003 + 0 + 1.253) - (2.251 + 0 + 0.541)
=-1.536

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Benitec Biopharma for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-54.328/( ( (1.02 + max(-1.528, 0)) + (0.916 + max(-1.536, 0)) )/ 2 )
=-54.328/( ( 1.02 + 0.916 )/ 2 )
=-54.328/0.968
=-5,612.40 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -5,612.40% mean?
Benitec Biopharma (BNTC) has a ROC (Joel Greenblatt) % of -5,612.40% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Benitec Biopharma and its competitors. According to the industry distribution chart, Benitec Biopharma ranks #1116 out of 1324 companies in the Biotechnology industry, placing it in the top 84.3%.
Is Benitec Biopharma's ROC (Joel Greenblatt) % too high?
Benitec Biopharma's current ROC (Joel Greenblatt) % is -5,612.40%. Based on the distribution chart, Benitec Biopharma ranks #1116 out of 1324 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's ROC (Joel Greenblatt) % compare to IPSC and FBRX?
According to the Biotechnology industry distribution chart, Benitec Biopharma ranks #1116 out of 1324 companies for ROC (Joel Greenblatt) %. This places Benitec Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Benitec Biopharma and its competitors. Benitec Biopharma's current ROC (Joel Greenblatt) % is -5,612.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (BNTC) has a current ROC (Joel Greenblatt) % of -5,612.40%. The current ROC (Joel Greenblatt) % is -5,612.40%. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Benitec Biopharma (BNTC), the current ROC (Joel Greenblatt) % is -5,612.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Benitec Biopharma Business Description

Address 3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score

Get the complete analysis for BNTC

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.21
Price